Morgan Stanley Increases NextCure (NASDAQ:NXTC) Price Target to $33.00

NextCure (NASDAQ:NXTC) had its target price increased by equities research analysts at Morgan Stanley from $25.00 to $33.00 in a research report issued on Tuesday, AnalystRatings.com reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 33.50% from the stock’s previous close.

NXTC has been the subject of several other reports. Piper Jaffray Companies assumed coverage on NextCure in a report on Monday, June 3rd. They issued an “overweight” rating and a $26.00 price objective for the company. Bank of America assumed coverage on NextCure in a report on Tuesday, July 9th. They set a “buy” rating and a $25.00 target price for the company.

Shares of NextCure stock opened at $24.72 on Tuesday. NextCure has a fifty-two week low of $13.86 and a fifty-two week high of $27.89. The company has a 50-day moving average price of $19.08.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.15). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, equities analysts anticipate that NextCure will post -2.14 EPS for the current year.

Several large investors have recently bought and sold shares of NXTC. Sofinnova Investments Inc. bought a new position in shares of NextCure during the second quarter valued at approximately $37,777,000. Citadel Advisors LLC bought a new position in shares of NextCure during the second quarter valued at approximately $16,385,000. Cormorant Asset Management LP bought a new position in shares of NextCure during the second quarter valued at approximately $14,980,000. Hillhouse Capital Management LTD. bought a new position in shares of NextCure during the second quarter valued at approximately $14,659,000. Finally, Matthews International Capital Management LLC bought a new position in shares of NextCure during the second quarter valued at approximately $6,741,000. 2.06% of the stock is owned by institutional investors.

NextCure Company Profile

There is no company description available for NextCure Inc

Featured Article: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.